Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

ClinicalTrials.gov ID: NCT04747977

Public ClinicalTrials.gov record NCT04747977. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.

Study identification

NCT ID
NCT04747977
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Enrollment
172 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 12, 2021 (Actual)
Primary completion
Aug 11, 2021 (Actual)
Completion
Sep 22, 2021 (Actual)
Last update posted
Feb 22, 2023

2021

United States locations

U.S. sites
15
U.S. states
10
U.S. cities
15
Facility City State ZIP Site status
Ocular Therapeutix Inglewood California 90301 —
Ocular Therapeutix, Inc Mission Hills California 91345 —
Ocular Therapeutix, Inc. Newport Beach California 92663 —
Ocular Therapeutix, Inc. Santa Ana California 92705 —
Ocular Therapeutix, Inc. Delray Beach Florida 33484 —
Ocular Therapeutix, Inc. Largo Florida 33773 —
Ocular Therapeutix Warrenville Illinois 60555 —
Ocular Therapeutix, Inc. Indianapolis Indiana 46260 —
Ocular Therapeutix Kansas City Missouri 64111 —
Ocular Therapeutix, Inc. St Louis Missouri 63131 —
Ocular Therapeutix Poughkeepsie New York 12603 —
Ocular Therapeutix, Inc. Raleigh North Carolina 27603 —
Ocular Therapeutix, Inc. Cranberry Township Pennsylvania 16066 —
Ocular Therapeutix, Inc. Memphis Tennessee 38119 —
Ocular Therapeutix, Inc. League City Texas 77573 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04747977, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 22, 2023 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04747977 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →